A phase 2, multicenter, double blind, randomized, fixed dose, parallel group, 3 week inpatient treatment study to evaluate the safety, efficacy and pharmacokinetics of PF-02545920 compared with placebo in the treatment of acute exacerbation of schizophrenia

Trial Profile

A phase 2, multicenter, double blind, randomized, fixed dose, parallel group, 3 week inpatient treatment study to evaluate the safety, efficacy and pharmacokinetics of PF-02545920 compared with placebo in the treatment of acute exacerbation of schizophrenia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2008

At a glance

  • Drugs Mardepodect (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Jun 2008 Actual end date is added as Feb 2008 as reported by ClinicalTrials.gov.
    • 11 May 2008 Actual no of patients added as 35 as reported by ClinicalTria;s.gov.
    • 11 May 2008 Actual start date changed from Dec 2007 to Nov 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top